Nifty
:
19674.25
Sensex
:
66009.15
-68.10 (-0.34%)
-221.09 (-0.33%)
Nifty
Sensex
:
:
19674.25
66009.15
-68.10 (-0.34%)
-221.09 (-0.33%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
68/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
595.60
22-Sep-2023
  • Open
  • High
  • Low
  • Previous Close
  •  616.00
  •  618.80
  •  594.30
  •  615.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1581468
  •  9508.52
  •  668.75
  •  350.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 60,286.88
  • 23.88
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 60,876.98
  • 1.01%
  • 3.24

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.98%
  • 0.68%
  • 5.97%
  • FII
  • DII
  • Others
  • 4.04%
  • 13.30%
  • 1.03%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.09
  • 5.54
  • 6.17

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.59
  • 3.70
  • 1.08

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.81
  • 0.75
  • -4.60

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.13
  • 21.38
  • 24.00

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.33
  • 3.21
  • 3.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.73
  • 13.79
  • 14.90

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Net Sales
5,139.60
3,964.30
29.65%
5,010.60
3,805.60
31.66%
4,362.30
3,639.80
19.85%
4,134.70
3,759.80
9.97%
Expenses
3,634.30
3,239.70
12.18%
3,755.00
3,087.90
21.60%
3,406.30
2,888.20
17.94%
3,319.40
2,860.30
16.05%
EBITDA
1,505.30
724.60
107.74%
1,255.60
717.70
74.95%
956.00
751.60
27.20%
815.30
899.50
-9.36%
EBIDTM
29.29%
18.28%
25.06%
18.86%
21.91%
20.65%
19.72%
23.92%
Other Income
36.00
174.30
-79.35%
37.80
79.10
-52.21%
38.50
60.70
-36.57%
44.40
53.30
-16.70%
Interest
18.10
34.30
-47.23%
27.70
38.50
-28.05%
32.80
31.10
5.47%
35.10
30.10
16.61%
Depreciation
179.80
180.70
-0.50%
178.60
185.40
-3.67%
181.60
177.00
2.60%
181.80
177.30
2.54%
PBT
1,329.20
681.00
95.18%
485.80
572.90
-15.20%
780.10
604.20
29.11%
642.80
858.10
-25.09%
Tax
216.10
118.40
82.52%
137.20
109.20
25.64%
195.20
109.40
78.43%
137.00
135.70
0.96%
PAT
1,113.10
562.60
97.85%
348.60
463.70
-24.82%
584.90
494.80
18.21%
505.80
722.40
-29.98%
PATM
21.66%
14.19%
6.96%
12.18%
13.41%
13.59%
12.23%
19.21%
EPS
10.74
5.06
112.25%
2.93
3.88
-24.48%
6.16
4.89
25.97%
5.16
29.32
-82.40%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
18,647.20
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
Net Sales Growth
22.93%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
 
Cost Of Goods Sold
6,475.20
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
Gross Profit
12,172.00
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
GP Margin
65.28%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
Total Expenditure
14,115.00
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
Power & Fuel Cost
-
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
129.70
% Of Sales
-
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
1.80%
Employee Cost
-
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
974.00
% Of Sales
-
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
13.48%
Manufacturing Exp.
-
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
936.50
% Of Sales
-
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
12.96%
General & Admin Exp.
-
737.70
506.70
444.00
582.60
583.40
398.70
466.00
356.40
326.80
302.70
% Of Sales
-
4.28%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
4.19%
Selling & Distn. Exp.
-
1,557.20
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
980.50
% Of Sales
-
9.03%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
13.57%
Miscellaneous Exp.
-
595.20
548.90
548.90
525.90
371.20
404.40
502.60
416.10
330.50
980.50
% Of Sales
-
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
4.09%
EBITDA
4,532.20
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
EBITDA Margin
24.30%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
Other Income
156.70
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
57.20
85.90
Interest
113.70
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
118.10
Depreciation
721.80
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
201.20
PBT
3,237.90
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
Tax
685.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
106.00
Tax Rate
21.17%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
PAT
2,552.40
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
PAT before Minority Interest
2,432.20
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
Minority Interest
-120.20
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
PAT Margin
13.69%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
PAT Growth
13.77%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
 
EPS
25.22
18.48
21.69
21.28
11.34
17.80
16.92
14.36
18.68
11.35
7.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
Share Capital
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
Non-Current Liabilities
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
Secured Loans
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
Unsecured Loans
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
Long Term Provisions
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
76.10
Current Liabilities
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
Trade Payables
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
Other Current Liabilities
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
Short Term Borrowings
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
Short Term Provisions
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
292.70
Total Liabilities
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
Net Block
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
Gross Block
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
Accumulated Depreciation
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
Non Current Assets
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
Capital Work in Progress
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
Non Current Investment
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
22.20
Long Term Loans & Adv.
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
511.10
Other Non Current Assets
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
0.00
Current Assets
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
Current Investments
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
64.40
Inventories
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
Sundry Debtors
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
Cash & Bank
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
Other Current Assets
985.70
229.90
523.90
441.60
1,080.50
1,048.40
348.50
358.90
311.50
323.50
Short Term Loans & Adv.
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
240.80
254.90
Net Current Assets
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
Total Assets
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
PBT
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
Adjustment
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
269.00
Changes in Working Capital
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
Cash after chg. in Working capital
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
-115.50
Cash From Investing Activity
1,171.20
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
Net Fixed Assets
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
Net Investments
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
Others
1,601.80
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
Cash from Financing Activity
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
Net Cash Inflow / Outflow
-540.40
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
Opening Cash & Equivalents
1,106.90
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
Closing Cash & Equivalent
573.10
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
33.58
ROA
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
ROE
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
ROCE
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
17.67%
Fixed Asset Turnover
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
1.63
Receivable days
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
56.38
51.71
Inventory Days
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
60.13
63.89
Payable days
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
49.83
Cash Conversion Cycle
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
65.78
Total Debt/Equity
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
0.79
Interest Cover
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29
8.98

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Zydus Lifesciences gets final nod for Clindamycin Phosphate Gel USP, 1%
    20th Sep 2023, 17:53 PM

    The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India)

    Read More
  • Zydus Lifesciences receives EIR for formulation manufacturing facility at Ahmedabad
    20th Sep 2023, 09:29 AM

    This was a Pre-Approval Inspection and had concluded with NIL observations

    Read More
  • Zydus Lifesciences acquires 6.5% stake in Mylab Discovery Solutions
    18th Sep 2023, 17:47 PM

    The company has completed the acquisition of 65,06,500 equity shares

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Norelgestromin and Ethinyl Estradiol Transdermal System
    15th Sep 2023, 14:30 PM

    The transdermal patch will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad

    Read More
  • Zydus Lifesciences gets EIR from USFDA for Ahmedabad injectables manufacturing facility
    13th Sep 2023, 14:50 PM

    The inspection was a cGMP Inspection and had ended with NIL observations

    Read More
  • Zydus Lifesciences incorporates wholly owned subsidiary in Canada
    8th Sep 2023, 14:19 PM

    The company has incorporated WOS on September 6, 2023 in Canada

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Erythromycin Tablets
    1st Sep 2023, 14:58 PM

    The drug will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Isotretinoin Capsules
    31st Aug 2023, 14:06 PM

    The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Zinc Sulfate Injection
    24th Aug 2023, 12:38 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at Jarod

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Doxepin Tablets
    17th Aug 2023, 16:19 PM

    Doxepin Tablets, 3 mg and 6 mg had annual sales of $43.4 million in the United States

    Read More
  • Zydus Lifesciences reports over 2-fold jump in Q1 consolidated net profit
    11th Aug 2023, 14:50 PM

    Total income of the company increased by 57.48% at Rs 3,038.10 crore for Q1FY24

    Read More
  • Zydus Lifesciences - Quarterly Results
    11th Aug 2023, 12:31 PM

    Read More
  • Zydus Lifesciences gets nod to manufacture, market 50mg Indomethacin suppositories
    3rd Aug 2023, 11:38 AM

    The company has been granted a CGT designation by the USFDA for its Indomethacin suppositories

    Read More
  • Zydus Lifesciences inks pact to amend clauses of JVA with Bayer
    27th Jul 2023, 15:12 PM

    An agreement to amend certain clauses of the JVA to enable participation in tenders of some government institutions / public sector undertakings

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Plerixafor Injection
    27th Jul 2023, 14:47 PM

    The drug will be manufactured at the group’s injectable manufacturing facility of Zydus Lifesciences (Alidac) at SEZ, Ahmedabad

    Read More
  • USFDA concludes inspection at Zydus’ group manufacturing facility in Ahmedabad
    8th Jul 2023, 11:43 AM

    The Pre-Approval Inspection closed with nil observations

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Oxcarbazepine Tablets
    4th Jul 2023, 12:11 PM

    The group now has 374 approvals and has so far filed over 442 ANDAs as of March 31, 2023 since the commencement of the filing process in FY 2003-04.

    Read More
  • Zydus Lifesciences gets EIR from USFDA for Ahmedabad manufacturing facility
    3rd Jul 2023, 11:50 AM

    The inspection has been classified as Voluntary Action Indicated

    Read More
  • Zydus Lifesciences gets tentative nod from USFDA for Palbociclib Tablets
    28th Jun 2023, 17:43 PM

    Palbociclib Tablets, 75 mg, 100 mg, and 125 mg had annual sales of $3.3 billion in the United States

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Minocycline Hydrochloride Extended-Release tablets
    19th Jun 2023, 15:29 PM

    The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.